Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Non Operating Income for 4 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • For Q4 2025, Non Operating Income fell 96.71% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $9.2 million, down 96.24%, while the annual FY2025 figure was $18.5 million, 85.69% down from the prior year.
  • Non Operating Income was $4.2 million for Q4 2025 at Day One Biopharmaceuticals, up from -$34000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $127.7 million in Q4 2024, with the low at -$12.2 million in Q4 2023.
  • Historically, Non Operating Income has averaged $16.7 million across 4 years, with a median of $1.2 million in 2024.
  • The largest annual shift saw Non Operating Income crashed 358.07% in 2023 before it surged 108975.0% in 2024.
  • Over 4 years, Non Operating Income stood at $4.7 million in 2022, then crashed by 358.07% to -$12.2 million in 2023, then surged by 1148.69% to $127.7 million in 2024, then plummeted by 96.71% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $4.2 million in Q4 2025, -$34000.0 in Q3 2025, and -$19000.0 in Q2 2025.